

18th November 2022

ASX ANNOUNCEMENT

ASX: RSH

ASX Market Announcements Platform
Sydney NSW

wheezo[®] REMOTE PATIENT MONITORING (RPM) PILOT PROGRAM SELECTED BY MINNESOTA LUNG CENTER A PREEMINENT PULMONARY CENTER OF EXCELLENCE IN THE USA.

Highlights:

- wheezo[®] and Access Telehealth RPM solutions has been selected for a pilot program to help manage patients suffering from asthma and Chronic Obstructive Pulmonary Disease (COPD) that are cared for by Minnesota Lung Center (MLC).
- Remote Patient Monitoring (RPM) solutions delivered through Access Telehealth will include a full-service premium model that includes patient engagement using their cloud-based platform, Remotli. This pilot program initially involves 20 patients and will be conducted over three months to ensure seamless integration into MLC’s systems and processes.
- With 9 pulmonologists, 6 mid-level healthcare workers, including nurses, respiratory therapists and medical assistants, and an extensive referral network, MLC is one of the largest private pulmonary practices in the Midwest providing care and other related respiratory healthcare services to thousands of patients. MLC also has a robust clinical research program.

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce that Minnesota Lung Center has chosen the wheezo[®] and RPM program for a pilot program to help manage patients with Chronic Obstructive Pulmonary Disease (COPD) and asthma. The program was secured with our RPM partner Access Telehealth and will provide a full RPM solution that includes the Remotli platform, patient engagement and remote monitoring under the supervision of MLC. Initially a pilot program involving 20 patients will be conducted with Wheezo[®] over a 3-month period to ensure that the RPM program seamlessly integrates into MLC systems and workflow.

RPM CPT reimbursement codes from this program will be processed through Centers for Medicare and Medicaid Services (CMS) and private insurers. On the successful completion of the pilot program, that includes integration and successful reimbursement, along with clinical benchmarks, it is anticipated that the wheezo[®] RPM program will be rolled out more broadly for MLC patients.

Minnesota Lung Center (MLC) was established in 1974 to provide comprehensive specialty care for people with respiratory health needs. MLC is committed to, and renowned for, high quality and compassionate care. They specialize in the treatment of patients with lung diseases and offer patients a wide variety of diagnostic services. MLC services are provided by 9 pulmonary physicians and other dedicated support staff including nurse practitioners, physician assistants, registered nurses, and respiratory therapists.

This is the first time that MLC will provide such a program that focuses on remote respiratory disease monitoring using the novel wheezo® device to track and monitor patient physiologic data between clinical visits and after acute care.

COPD in-patient medical services costs USD\$27,597 and asthma USD\$8,238 per admission. Under the supervision of MLC physicians, the wheezo®/Access Telehealth innovative technology aims to enable a cost effective and powerful way to frequently evaluate patient physiologic data and to stay connected with more vulnerable patients to extend care beyond the clinic with a goal of reducing hospitalizations, exacerbations, and other related problems that contribute to escalating healthcare costs in the USA.

Marjan Mikel, CEO of Respi said, “The Minnesota Lung Center opportunity is a watershed moment for Respi given they are the first major respiratory healthcare organization to choose our wheezo® RPM solution. We are excited about working together with the MLC team to provide even better care for patients and improving their quality of life.”

Dr Jonathan Hovda, MLC Pulmonary Physician, said “Minnesota Lung Center is excited for the opportunity to be working with Respi on evaluating the wheezo® device and working with Access Telehealth on RPM logistics, processes, and reimbursement. Using wheezo® to monitor patients with asthma and COPD and can help identify early changes in symptoms which can help us manage our patients.”

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respi Limited
P: +61 408 462 873
E: marjan@respi.co

Mr Nicholas Smedley
Executive Chairman
Respi Limited
P: +61 447 074 160
E: nicholas@respi.co

wheezo® is a registered trademark of Respi Limited.

About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit www.respi.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com> wheezo® is a registered trademark of Respi Limited.